Publications by authors named "T M A Kerkhofs"
Background: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.
Patients And Methods: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry.
We aimed to develop a disease-specific adrenocortical carcinoma (ACC) health-related quality of life (HRQoL) questionnaire (ACC-QOL) and assess HRQoL in a population-based cohort of patients with ACC. Development was in line with European Organization for Research and Treatment of Cancer (EORTC) guidelines, though not an EORTC product. In phase I and II, we identified 90 potential HRQoL issues using literature and focus groups, which were reduced to 39 by healthcare professionals.
View Article and Find Full Text PDFIntroduction: Mitotane is the only drug registered specifically for adrenocortical carcinoma. Finding the optimal dose for a patient is difficult due to large differences in bioavailability, toxicity and effect. We therefore look to improve personalized dosing of mitotane.
View Article and Find Full Text PDFArticle Synopsis
- Mitotane is the only approved treatment for adrenocortical carcinoma (ACC), and this study aims to understand how its pharmacokinetics (PK) vary among patients to improve treatment.
- Researchers developed a population PK model using data from 48 ACC patients, analyzing factors like body weight and genetic variations that influence mitotane clearance.
- The study found that certain genetic factors and lean body weight significantly affect drug clearance, and simulations suggest that using the model can help optimize starting doses to achieve effective treatment while minimizing toxicity.
DNA methylation profiling has been suggested a reliable technique to distinguish between benign and malignant adrenocortical tumors, a process which with current diagnostic methods remains challenging and lacks diagnostic accuracy of borderline tumors. Accurate distinction between benign and malignant adrenal tumors is of the essence, since ACC is a rare but aggressive endocrine disease with an annual incidence of about 2.0 cases per million people per year.
View Article and Find Full Text PDF